CD200 Antagonist Antibodies Modulating Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and autoimmune disorders often rely on immunosuppressive agents that can cause undesirable side effects and are not specific enough, and humanized or chimeric monoclonal antibodies are needed to reduce immune responses and enhance therapeutic effectiveness.
Innovation Solution
Development of CD200 antagonists, including anti-CD200 antibodies with altered effector functions, to modulate the function of CD200, either by inhibiting its interaction with its receptor or directly targeting CD200-positive cells, thereby promoting the eradication of cancer cells or reducing autoimmune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive agents are used to treat autoimmune disorders, then immune suppression is achieved, but side effects and lack of specificity increase
Solution Approach 1:
The patent segments the immune system response by targeting specific CD200-expressing cell populations (such as regulatory T cells, B cells, or myeloid cells) rather than suppressing the entire immune system. This is achieved through antibodies that selectively bind to CD200 on specific cell types, allowing differential modulation of immune responses - suppressing pathological autoimmunity while preserving protective immunity against infections and tumors.
Solution Approach 2:
The invention applies local quality by creating antibodies with specific effector function profiles tailored to target CD200 on particular cell types. Different antibody variants are designed with specific Fc regions that engage different Fc receptors, enabling localized immune suppression at the level of specific cell populations and tissue microenvironments where CD200 is pathologically overexpressed, rather than systemic immunosuppression.
2Reliability
If conventional monoclonal antibodies are used, then therapeutic effect is achieved, but immune response against the antibody increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the Fc region parameters of monoclonal antibodies to alter their effector functions. Different Fc variants (such as IgG1, IgG2, IgG3, IgG4 subclasses and engineered Fc mutations) are used to tune the antibody's binding affinity to Fc receptors, complement activation potential, and half-life. This allows optimization of therapeutic effect while minimizing immunogenicity by selecting Fc parameters that reduce recognition by human anti-mouse antibody responses.
3Reliability
If CD200 interaction with receptor is blocked, then immune suppression is reduced, but direct killing of cancer cells is needed
Solution Approach 1:
The patent employs multi-functionality by designing antibody compositions that simultaneously perform multiple mechanisms of action: (1) blocking CD200-CD200R interaction to prevent immune suppression and restore anti-tumor immunity, (2) mediating antibody-dependent cellular cytotoxicity (ADCC) through Fc receptor engagement, and (3) inducing complement-dependent cytotoxicity (CDC) through complement activation. This combination of mechanisms within a single therapeutic agent addresses both the immune suppression barrier and the need for direct cancer cell elimination.
Data Source
AI summary
This application provides methods and compositions for modulating and/or depleting CD200 positive cells.